ValuEngine upgraded shares of Teligent (NASDAQ:TLGT) from a hold rating to a buy rating in a research note issued to investors on Friday.
Separately, Canaccord Genuity set a $4.00 price objective on shares of Teligent and gave the company a hold rating in a research report on Tuesday, July 31st.
Teligent stock traded up $0.20 during mid-day trading on Friday, reaching $3.46. 135,571 shares of the company’s stock were exchanged, compared to its average volume of 232,786. Teligent has a twelve month low of $2.43 and a twelve month high of $5.43. The company has a current ratio of 2.77, a quick ratio of 1.79 and a debt-to-equity ratio of 3.31.
Teligent (NASDAQ:TLGT) last announced its quarterly earnings data on Wednesday, August 8th. The company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.18). Teligent had a negative net margin of 62.19% and a negative return on equity of 50.85%. The firm had revenue of $16.75 million during the quarter, compared to analysts’ expectations of $16.06 million. As a group, equities analysts forecast that Teligent will post -0.13 EPS for the current fiscal year.
In other Teligent news, CEO Jason Grenfell-Gardner sold 52,800 shares of the stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $4.00, for a total value of $211,200.00. Following the sale, the chief executive officer now directly owns 94,949 shares of the company’s stock, valued at approximately $379,796. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 22.80% of the company’s stock.
Large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its position in shares of Teligent by 225.7% in the 1st quarter. JPMorgan Chase & Co. now owns 33,731 shares of the company’s stock valued at $274,000 after purchasing an additional 23,376 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its position in shares of Teligent by 83.9% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 94,443 shares of the company’s stock valued at $327,000 after buying an additional 43,091 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Teligent by 15.9% in the 3rd quarter. Wells Fargo & Company MN now owns 123,329 shares of the company’s stock valued at $488,000 after buying an additional 16,919 shares during the last quarter. Guggenheim Capital LLC grew its position in shares of Teligent by 8.7% in the 1st quarter. Guggenheim Capital LLC now owns 383,466 shares of the company’s stock valued at $1,288,000 after buying an additional 30,532 shares during the last quarter. Finally, Northpointe Capital LLC purchased a new position in shares of Teligent in the 3rd quarter valued at $2,948,000. 68.27% of the stock is currently owned by institutional investors.
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Featured Article: Put Option
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.